A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration
A Phase I Study to Assess the Safety and Immunogenicity of Novel Routes of Administration of Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP.
Sponsor: University of Oxford
A PHASE1 clinical study on Malaria, this trial is completed. The trial is conducted by University of Oxford and has accumulated 11 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Nov 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2019 — Sep 2020 [monthly]
Recruiting PHASE1
-
Nov 2018 — Jun 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — May 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .